联合使用CLivD评分与FIB-4预测人群中的肝脏相关结局
在UK Biobank队列的369,832名基线无肝病成人中外部验证慢性肝病(CLivD)评分预测肝脏相关结局(LROs),并探讨CLivD与纤维化-4(FIB-4)序贯联合使用。10年随访时,CLivD lab(含γ-谷氨酰转移酶)预测LRO的AUC为0.80,CLivD non-lab为0.72,FIB-4为0.75。FIB-4预测性能随CLivD评分升高而提升;联合使用可识别出10年内每3人中约1人发生LRO的高危亚组。
要点
- CLivD评分是LRO风险评定的有效工具,可提升FIB-4的预测性能。
- 10年随访时,CLivD lab预测LRO的AUC为0.80,高于FIB-4的0.75和CLivD non-lab的0.72。
- CLivD与FIB-4联合可识别10年内约1/3个体发生LRO的高危亚组。
核心结论
- CLivD评分是LRO风险评定的有效工具,并提高FIB-4的预测性能。
- CLivD与FIB-4联合使用识别出一个亚组,其中每3人中有1人在10年内发生LRO。
研究设计与样本
- 在UK Biobank队列中外部验证CLivD评分对LRO的预测,并研究CLivD与FIB-4序贯联合使用。
- 分析纳入369,832名基线无肝病且具备CLivD与FIB-4计算数据的成人。
- LRO包括代偿或失代偿性肝硬化或HCC,通过电子健康登记链接确认。
- 采用竞争风险方法评估判别性能和累积发病率。
主要发现
- 10年随访时,预测LRO的时间依赖AUC:CLivD lab为0.80,CLivD non-lab为0.72,FIB-4为0.75。
- CLivD lab对肝脏相关死亡和严重酒精相关性肝脏结局的AUC超过0.85。
- FIB-4的预测性能随CLivD评分升高而提升;10年FIB-4 AUC从CLivD极小风险亚组的0.60升至CLivD高风险亚组的0.81。
- 在CLivD极小风险亚组中,LRO累积发病率在FIB-4低至高分层间为0.05%至0.3%。
- 在CLivD高风险亚组中,相应发病率为1.7%至21.1%,FIB-4>3.25者达33%。
关键数值与推荐
- CLivD lab(含γ-谷氨酰转移酶)10年预测LRO的AUC为0.80。
- CLivD non-lab(不含实验室值)10年预测LRO的AUC为0.72。
- FIB-4 10年预测LRO的AUC为0.75。
- CLivD高风险亚组中FIB-4>3.25者10年LRO累积发病率为33%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A need exists for effective and practical tools to identify individuals at increased risk of liver-related outcomes (LROs) within the general population. APPROACH AND RESULTS: We externally validated the chronic liver disease (CLivD) score for LROs in the UK Biobank cohort. We also investigated the sequential combined use of CLivD and fibrosis-4 (FIB-4) scores. Our analysis included 369,832 adults without baseline liver disease and with available data for CLivD and FIB-4 computation. LROs reflecting compensated or decompensated liver cirrhosis or HCC were ascertained through linkages with electronic health care registries. Discriminatory performance and cumulative incidence were evaluated with competing-risk methodologies. Over a 10-year follow-up, time-dependent AUC values for LRO prediction were 0.80 for CLivD lab (including gamma-glutamyltransferase), 0.72 for CLivD non-lab (excluding laboratory values), and 0.75 for FIB-4. CLivD lab demonstrated AUC values exceeding 0.85 for liver-related death and severe alcohol-associated liver outcomes. The predictive performance of FIB-4 increased with rising CLivD scores; 10-year FIB-4 AUC values ranged from 0.60 within the minimal-risk CLivD subgroup to 0.81 within the high-risk CLivD subgroup. Moreover, in the minimal-risk CLivD subgroup, the cumulative incidence of LRO varied from 0.05% to 0.3% across low-to-high FIB-4 strata. In contrast, within the high-risk CLivD subgroup, the corresponding incidence ranged from 1.7% to 21.1% (up to 33% in individuals with FIB-4 >3.25). CONCLUSIONS: The CLivD score is a valid tool for LRO risk assessment and improves the predictive performance of FIB-4. The combined use of CLivD and FIB-4 identified a subgroup where 1 in 3 individuals developed LROs within 10 years.
引用
- Åberg F, Asteljoki J, Männistö V, et al. Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population. Hepatology. 2023. PMID: 38112489. doi:10.1097/HEP.0000000000000707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。